ROQUEFORT THERAPEUTICS PLC Logo

ROQUEFORT THERAPEUTICS PLC

Biotechnology company developing medicines for therapy-resistant cancers.

ROQ | IL

Overview

Corporate Details

ISIN(s):
GB00BMDQ2T15
LEI:
254900P4SISIWOR9RH34
Country:
United Kingdom
Address:
85 Great Portland Street, W1W 7LT London

Description

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-12-21 10:06
Second Price Monitoring Extn
English 2.8 KB
2021-12-21 10:00
Price Monitoring Extension
English 2.8 KB
2021-12-21 08:00
Acquisition Completion, Admission & Voting Rights
English 13.2 KB
2021-12-16 18:19
Prospectus dated 16 December 2021
English 594.7 KB
2021-12-16 17:24
Publication of Prospectus
English 17.8 KB
2021-12-14 12:07
Resolutions passed at general meeting
English 15.3 KB
2021-12-13 14:19
Results of General Meeting
English 16.2 KB
2021-11-22 08:00
Conditional Placing to Raise £3 Million
English 23.2 KB
2021-11-19 08:00
Circular and Notice of General Meeting
English 7.1 KB
2021-11-18 08:00
Proposed Acquisition of Lyramid Pty Limited
English 82.9 KB
2021-11-12 08:33
Update on Acquisition of Lyramid Limited
English 7.6 KB
2021-10-29 15:40
Interim Results to 30 June 2021
English 366.1 KB
2021-10-29 15:01
Interim Results to 30 June 2021
English 157.1 KB
2021-10-20 08:08
Board Changes
English 211.9 KB
2021-10-20 08:00
Board Changes
English 9.1 KB

Automate Your Workflow. Get a real-time feed of all ROQUEFORT THERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ROQUEFORT THERAPEUTICS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ROQUEFORT THERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.